Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic ... MarketWatch ... OMS721 Phase 2 clinical trial, planned to begin later this quarter, will evaluate the effects of the drug on patients with TMAs, including atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and stem cell ... |
